Skip to main content
syn
Daily Digest
Science & Health

Daily pill helps maintain weight after obesity jabs

Published Tuesday, May 12, 2026 · Updated May 13

Share on X

Source Balance

Limited Data
Left 0%Center 100%Right 0%

Coverage is limited to a single source, BBC News, which may not represent a full spectrum of perspectives.

Media Analysis

AI synthesis

A new daily pill called orforglipron has demonstrated effectiveness in helping patients maintain weight loss after they stop using GLP-1 obesity injections. Clinical trials showed that participants taking orforglipron kept off over 70% of their previously lost weight, compared to a placebo group that maintained only 38-50% of their loss.

What We Know — Key Points

  • Participants in trials who took the new daily pill orforglipron maintained over 70% of their initial weight loss, significantly more than the placebo group which retained approximately 38-50%.
  • The new daily pill is named orforglipron.
  • Orforglipron is designed to help individuals maintain weight loss after they have stopped taking GLP-1 obesity injections.

What Is Claimed — Perspectives

  • BBC NewsCenter

    A new daily pill, orforglipron, has shown promise in helping individuals maintain weight loss after discontinuing GLP-1 obesity injections. Trials indicated that patients taking the pill retained over 70% of their lost weight, addressing a common issue of weight regain.

AI-Generated Content

  • This topic was generated by an AI system.
  • Key points, perspectives, bias labels, and categorisation may contain errors.
  • This is not journalism. Do not rely on this content for critical decisions.
  • Read our full AI disclaimer for details.